Champagne-sur-Oise, Ile-de-France Jul 13, 2022 (Issuewire.com) - JETABLE INTERNATIONAL, INC., announced today the official launch of a new medicated anti-fatigue travel remedy called; JET-LAG-SPRAY. In the future Airline flight crews and frequent flyers might improve their mental and physical sharpness using a potassium iodide-based electrolyte anti-fatigue oral spray. The results of a prospective clinical study suggest that JET-LAG-SPRAY can be used as a safe and effective alternative to conventional Airport Kiosk homeopathic formulations such as "No-Jet-Lag" or "JetLagFX" used to remain focused and alert during long-haul international flights. JET-LAG-SPRAY helps boost natural immunity, protecting against harmful radioactive iodine, colds, and the flu bug.
JET-LAG-SPRAY is a special blend of Potassium Iodide and bioactive compounds that are designed to help maintain one's immune system naturally. Airline travel across multiple time zones produces jet lag, which includes difficulty initiating or maintaining nighttime sleep, daytime sleepiness, decreased alertness, loss of concentration, impaired performance, fatigue, irritability, disorientation, depressed mood, and gastrointestinal disturbance. Jet lag poses a threat to public safety as it affects civilian and military pilots.
"With Airport Kiosk product placement, we are able to increase last-minute impulse purchases of JET-LAG-SPRAY, bought by frequent flyers about to board international long-haul flights,” said Richard H, DAVIS, Président Directeur Général de JETABLE INTERNATIONAL, INC. "No one ever plans ahead for jet lag prevention, Air Travelers just buy the product when they see it," said DAVIS.
ABOUT JETABLE INTERNATIONAL, INC.
JETABLE INTERNATIONAL, INC., is a leading biotechnology company focused on the discovery, development, and commercialization of novel biomedical technologies to address cognitive issues in neurodegenerative diseases and other age-related aspects of aging and memory loss.
DISCLAIMER:
This material expresses the firm's opinion for informational purposes only and does not consider the investment objectives, financial situation, or individual needs of one or a particular group of investors. We recommend consulting specialized professionals for investment decisions. Investors are advised to carefully read the Investment Fund's prospectus or regulations before investing their funds. The information and conclusions contained in this material may be changed at any time, without prior notice. This material may not be copied, reproduced, or distributed without the prior and express agreement of JETABLE INTERNATIONAL, INC.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.
† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
To find out more, visit: https://jetable.webnode.co.uk
INVESTORS CONTACT:
Richard H. DAVIS
Président Directeur Général
JETABLE INTERNATIONAL, INC.
Tel: +33 7 5713 0799 | investors@jetable.fr.nf
SOURCE: JETABLE INTERNATIONAL, INC.
Media Contact
JETABLE INTERNATIONAL, INC. investors@jetable.fr.nf Tel: +33 7 5713 0799 https://jetable.webnode.co.uk
